<div><b>Discussion</b></div><div>Coronavirus disease 2019
(COVID-19),
which was identified due to the case of viral pneumonia in 2019, and was
named by the world health organization on January 12,
2020<sup>[1]</sup>.Coronavirus is a large family of viruses
known to cause serious illnesses such as MERS and
SARS<sup>[5]</sup>.The novel coronavirus is a new strain of
coronavirus that has never been found in humans before.Since December
2019, A lot of viral pneumonia cases have been detected, which have been
diagnosed as viral pneumonia infection.People infected with coronavirus
after the common signs of respiratory symptoms, fever, cough, gas and
breathing difficulties.In more severe cases, the infection can lead to
pneumonia, severe acute respiratory syndrome, kidney failure, and even
death<sup>[6, 7]</sup>.There is no specific treatment for
diseases caused by novel coronaviruses
currently<sup>[8]</sup>. The generally susceptible and high
mortality associated with COVID-19 led us to conduct this systematic
review and meta-analysis to summarize the available options for
treatment of novel coronavirus infection based on previous reports of
therapy of SARS,MERS.</div><div>Convalescent
plasma plays an important role in the treatment of SARS and MERS for
severe respiratory infections<sup>[9]</sup>.Cheng
[<sup>10]</sup>found that convalescent plasma therapy had
benefits effect for SARS，especialy in the early phase.
Soo<sup>[11</sup>]Conformed that Patients with convalescent
plasma therapy had a shorter hospital stay, lower mortality and no
immediate adverse effects were observed. Yeh<sup>[12]</sup>made a conclusion that infected SARS in Taiwan hospital whose condition
had progressed severely survived after transfusion with convalescent
plasma. Chun <sup>[13]</sup>reported Transfusion-Related
Acute Lung Injury occured afer Convalescent Plasma Transfusion in a
Patient With Middle East Respiratory Syndrome. Jae-Hoon
Ko<sup>[14]</sup> reported donor convalescent plasma with a
neutralization activity of a PRNT titer 1:80 should be used in MERS.</div><div>This study revealed that the therapy of Convalescent plasma can reduce
mortality of patients with Coronavirus.The study provided a high sample
size and the conclusions drawn by the study are highly credible because
of the comprehensive data collection strategy. However,there were
several limitations to this study. The distribution of studies between
locations was not uniform. we were able to find and extract data for the
meta-analysis from Hong Kong, Taiwan, Korea. In additional , most of the
selected studies were from hospital and no&nbsp;strict control group. There
was no convalescent plasma for the treatment of patients with
Coronavirus in the early stages. there may be reporting bias in some
details. Moreover,The systematic review is likely to have publication
bias as some articals used other languages .Therefore, the conclusions
of this Meta-analysis still need to be verified by further studies to
clarify the associations.</div><div>We hope this study will provide important information for policy-makers
pay more attention to The effectiveness of convalescent plasma for the
treatment of patients with Coronavirus , Improve survival of critically
ill patients<sup>[15]</sup>.</div><div></div><div><b>Acknowledgements</b>: The authors declare no conflict of interest in this
study.</div><div></div><div><b>References</b></div><div>[1] S. Dong, J. Sun, Z. Mao, L. Wang, Y.L. Lu, J. Li, A guideline
for homology modeling of the proteins from newly discovered
betacoronavirus, 2019 novel coronavirus (2019-nCoV), Journal of medical
virology, (2020).</div><div>[2] X.Y. Li, B. Du, Y.S. Wang, H.Y.J. Kang, F. Wang, B. Sun, H.B.
Qiu, Z.H. Tong, [The keypoints in treatment of the critical
coronavirus disease 2019 patient], Zhonghua jie he he hu xi za zhi =
Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and
respiratory diseases, 43 (2020) E026.</div><div>[3] C. Chen, X.R. Zhang, Z.Y. Ju, W.F. He, [Advances in the
research of cytokine storm mechanism induced by Corona Virus Disease
2019 and the corresponding immunotherapies], Zhonghua shao shang za
zhi = Zhonghua shaoshang zazhi = Chinese journal of burns, 36 (2020)
E005.</div><div>[4] H. Momattin, K. Mohammed, A. Zumla, Z.A. Memish, J.A. Al-Tawfiq,
Therapeutic options for Middle East respiratory syndrome coronavirus
(MERS-CoV)–possible lessons from a systematic review of SARS-CoV
therapy, Int J Infect Dis, 17 (2013) e792-798.</div><div>[5] J.A. Al-Tawfiq, Viral loads of SARS, MERS and SARS-CoV-2 in
respiratory specimens: What have we learned?, Travel medicine and
infectious disease, (2020) 101629.</div><div>[6] G.Q. Qian, N.B. Yang, F. Ding, A.H.Y. Ma, Z.Y. Wang, Y.F. Shen,
C.W. Shi, X. Lian, J.G. Chu, L. Chen, Z.Y. Wang, D.W. Ren, G.X. Li, X.Q.
Chen, H.J. Shen, X.M. Chen, Epidemiologic and Clinical Characteristics
of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A
retrospective, multi-centre case series, QJM : monthly journal of the
Association of Physicians, (2020).</div><div>[7] Z. Wang, B. Yang, Q. Li, L. Wen, R. Zhang, Clinical Features of
69 Cases with Coronavirus Disease 2019 in Wuhan, China, Clinical
infectious diseases : an official publication of the Infectious Diseases
Society of America, (2020).</div><div>[8] A.C. Cunningham, H.P. Goh, D. Koh, Treatment of COVID-19: old
tricks for new challenges, Critical care (London, England), 24 (2020)
91.</div><div>[9] Y.M. Arabi, A.H. Hajeer, T. Luke, K. Raviprakash, H. Balkhy, S.
Johani, A. Al-Dawood, S. Al-Qahtani, A. Al-Omari, F. Al-Hameed, F.G.
Hayden, R. Fowler, A. Bouchama, N. Shindo, K. Al-Khairy, G. Carson, Y.
Taha, M. Sadat, M. Alahmadi, Feasibility of Using Convalescent Plasma
Immunotherapy for MERS-CoV Infection, Saudi Arabia, Emerg Infect Dis, 22
(2016) 1554-1561.</div><div>[10] Y. Cheng, R. Wong, Y.O. Soo, W.S. Wong, C.K. Lee, M.H. Ng, P.
Chan, K.C. Wong, C.B. Leung, G. Cheng, Use of convalescent plasma
therapy in SARS patients in Hong Kong, Eur J Clin Microbiol Infect Dis,
24 (2005) 44-46.</div><div>[11] &lt;soo2004.pdf&gt;.</div><div>[12] K.M. Yeh, T.S. Chiueh, L.K. Siu, J.C. Lin, P.K. Chan, M.Y.
Peng, H.L. Wan, J.H. Chen, B.S. Hu, C.L. Perng, J.J. Lu, F.Y. Chang,
Experience of using convalescent plasma for severe acute respiratory
syndrome among healthcare workers in a Taiwan hospital, J Antimicrob
Chemother, 56 (2005) 919-922.</div><div>[13] S. Chun, C.R. Chung, Y.E. Ha, T.H. Han, C.S. Ki, E.S. Kang,
J.K. Park, K.R. Peck, D. Cho, Possible Transfusion-Related Acute Lung
Injury Following Convalescent Plasma Transfusion in a Patient With
Middle East Respiratory Syndrome, Ann Lab Med, 36 (2016) 393-395.</div><div>[14] J.H. Ko, H. Seok, S.Y. Cho, Y.E. Ha, J.Y. Baek, S.H. Kim, Y.J.
Kim, J.K. Park, C.R. Chung, E.S. Kang, D. Cho, M.A. Muller, C. Drosten,
C.I. Kang, D.R. Chung, J.H. Song, K.R. Peck, Challenges of convalescent
plasma infusion therapy in Middle East respiratory coronavirus
infection: a single centre experience, Antiviral therapy, 23 (2018)
617-622.</div><div>[15] G.J.G. Asmundson, S. Taylor, How health anxiety influences
responses to viral outbreaks like COVID-19: What all decision-makers,
health authorities, and health care professionals need to know, Journal
of anxiety disorders, 71 (2020) 102211.</div>